215 related articles for article (PubMed ID: 15095852)
21. Budesonide CIR capsules (once or twice daily divided-dose) in active Crohn's disease: a randomized placebo-controlled study in the United States.
Tremaine WJ; Hanauer SB; Katz S; Winston BD; Levine JG; Persson T; Persson A;
Am J Gastroenterol; 2002 Jul; 97(7):1748-54. PubMed ID: 12135030
[TBL] [Abstract][Full Text] [Related]
22. Budesonide for maintenance of remission in patients with Crohn's disease in medically induced remission: a predetermined pooled analysis of four randomized, double-blind, placebo-controlled trials.
Sandborn WJ; Löfberg R; Feagan BG; Hanauer SB; Campieri M; Greenberg GR
Am J Gastroenterol; 2005 Aug; 100(8):1780-7. PubMed ID: 16086715
[TBL] [Abstract][Full Text] [Related]
23. Budesonide as maintenance treatment in Crohn's disease: a placebo-controlled trial.
Hanauer S; Sandborn WJ; Persson A; Persson T
Aliment Pharmacol Ther; 2005 Feb; 21(4):363-71. PubMed ID: 15709986
[TBL] [Abstract][Full Text] [Related]
24. Comparison of two dosing methods for induction of response and remission with oral budesonide in active pediatric Crohn's disease: a randomized placebo-controlled trial.
Levine A; Kori M; Dinari G; Broide E; Shaoul R; Yerushalmi B; On A; Bujanover Y; Pröls M; Greinwald R;
Inflamm Bowel Dis; 2009 Jul; 15(7):1055-61. PubMed ID: 19229988
[TBL] [Abstract][Full Text] [Related]
25. Oral budesonide versus prednisolone in patients with active extensive and left-sided ulcerative colitis.
Löfberg R; Danielsson A; Suhr O; Nilsson A; Schiöler R; Nyberg A; Hultcrantz R; Kollberg B; Gillberg R; Willén R; Persson T; Salde L
Gastroenterology; 1996 Jun; 110(6):1713-8. PubMed ID: 8964395
[TBL] [Abstract][Full Text] [Related]
26. Budesonide for Crohn's disease.
Seow CH; Benchimol EI; Steinhart AH; Griffiths AM; Otley AR
Expert Opin Drug Metab Toxicol; 2009 Aug; 5(8):971-9. PubMed ID: 19611401
[TBL] [Abstract][Full Text] [Related]
27. Budesonide versus prednisolone retention enemas in active distal ulcerative colitis.
Löfberg R; Ostergaard Thomsen O; Langholz E; Schiöler R; Danielsson A; Suhr O; Graffner H; Påhlman L; Matzen P; Møller-Petersen JF
Aliment Pharmacol Ther; 1994 Dec; 8(6):623-9. PubMed ID: 7696452
[TBL] [Abstract][Full Text] [Related]
28. Budesonide for induction of remission in Crohn's disease.
Seow CH; Benchimol EI; Griffiths AM; Otley AR; Steinhart AH
Cochrane Database Syst Rev; 2008 Jul; (3):CD000296. PubMed ID: 18646064
[TBL] [Abstract][Full Text] [Related]
29. Contribution of plasma cortisol to corticosteroid-suppressed peripheral blood natural killer cell activity in Crohn's disease.
van Ierssel GJ; van der Sluys Veer A; Verspaget HW; Griffioen G; van Hogezand RA; Lamers CB
Immunopharmacology; 1995 Feb; 29(1):11-7. PubMed ID: 7768667
[TBL] [Abstract][Full Text] [Related]
30. Budesonide. A review of its pharmacological properties and therapeutic efficacy in inflammatory bowel disease.
Spencer CM; McTavish D
Drugs; 1995 Nov; 50(5):854-72. PubMed ID: 8586030
[TBL] [Abstract][Full Text] [Related]
31. Budesonide and mesalazine in active Crohn's disease: a comparison of the effects on quality of life.
Thomsen OO; Cortot A; Jewell D; Wright JP; Winter T; Veloso FT; Vatn M; Persson T; Pettersson E;
Am J Gastroenterol; 2002 Mar; 97(3):649-53. PubMed ID: 11922560
[TBL] [Abstract][Full Text] [Related]
32. Oral pH-modified release budesonide versus 6-methylprednisolone in active Crohn's disease. German/Austrian Budesonide Study Group.
Gross V; Andus T; Caesar I; Bischoff SC; Lochs H; Tromm A; Schulz HJ; Bär U; Weber A; Gierend M; Ewe K; Schölmerich J
Eur J Gastroenterol Hepatol; 1996 Sep; 8(9):905-9. PubMed ID: 8889459
[TBL] [Abstract][Full Text] [Related]
33. Bone turnover during short-term therapy with methylprednisolone or budesonide in Crohn's disease.
D'Haens G; Verstraete A; Cheyns K; Aerden I; Bouillon R; Rutgeerts P
Aliment Pharmacol Ther; 1998 May; 12(5):419-24. PubMed ID: 9663720
[TBL] [Abstract][Full Text] [Related]
34. Combined budesonide and antibiotic therapy for active Crohn's disease: a randomized controlled trial.
Steinhart AH; Feagan BG; Wong CJ; Vandervoort M; Mikolainis S; Croitoru K; Seidman E; Leddin DJ; Bitton A; Drouin E; Cohen A; Greenberg GR
Gastroenterology; 2002 Jul; 123(1):33-40. PubMed ID: 12105831
[TBL] [Abstract][Full Text] [Related]
35. Budesonide prolongs time to relapse in ileal and ileocaecal Crohn's disease. A placebo controlled one year study.
Löfberg R; Rutgeerts P; Malchow H; Lamers C; Danielsson A; Olaison G; Jewell D; Ostergaard Thomsen O; Lorenz-Meyer H; Goebell H; Hodgson H; Persson T; Seidegård C
Gut; 1996 Jul; 39(1):82-6. PubMed ID: 8881815
[TBL] [Abstract][Full Text] [Related]
36. The effectiveness of budesonide therapy for Crohn's disease.
Kane SV; Schoenfeld P; Sandborn WJ; Tremaine W; Hofer T; Feagan BG
Aliment Pharmacol Ther; 2002 Aug; 16(8):1509-17. PubMed ID: 12182751
[TBL] [Abstract][Full Text] [Related]
37. Maintenance treatment with budesonide 6 mg versus 9 mg once daily in patients with Crohn's disease in remission.
de Jong DJ; Bac DJ; Tan G; de Boer SY; Grabowsky IL; Jansen JB; Greinwald R; Naber TH
Neth J Med; 2007 Oct; 65(9):339-45. PubMed ID: 17954953
[TBL] [Abstract][Full Text] [Related]
38. Once versus three times daily dosing of oral budesonide for active Crohn's disease: a double-blind, double-dummy, randomised trial.
Dignass A; Stoynov S; Dorofeyev AE; Grigorieva GA; Tomsová E; Altorjay I; Tuculanu D; Bunganič I; Pokrotnieks J; Kupčinskas L; Dilger K; Greinwald R; Mueller R;
J Crohns Colitis; 2014 Sep; 8(9):970-80. PubMed ID: 24534142
[TBL] [Abstract][Full Text] [Related]
39. Budesonide versus mesalamine for maintaining remission in patients refusing other immunomodulators for steroid-dependent Crohn's disease.
Mantzaris GJ; Petraki K; Sfakianakis M; Archavlis E; Christidou A; Chadio-Iordanides H; Triadaphyllou G
Clin Gastroenterol Hepatol; 2003 Mar; 1(2):122-8. PubMed ID: 15017504
[TBL] [Abstract][Full Text] [Related]
40. A randomized, double-blind, placebo-controlled trial of CDP571, a humanized monoclonal antibody to tumour necrosis factor-alpha, in patients with corticosteroid-dependent Crohn's disease.
Feagan BG; Sandborn WJ; Baker JP; Cominelli F; Sutherland LR; Elson CO; Salzberg BA; Archambault A; Bernstein CN; Lichtenstein GR; Heath PK; Cameron S; Hanauer SB
Aliment Pharmacol Ther; 2005 Feb; 21(4):373-84. PubMed ID: 15709987
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
